ASCO GU 2023 - Results from #80

Viewing 81-100 of 190 articles

ASCO GU 2023: Updated Outcomes in TROPHY-U-01 Cohort 1, a Phase 2 Study of Sacituzumab Govitecan in Patients with Metastatic Urothelial Cancer That Progressed after Platinum-Based Chemotherapy and a Checkpoint Inhibitor

ASCO GU 2023: Genomic Alterations in Patients with Prostate Cancer with Liver Metastases

ASCO GU 2023: Study of Real-World Treatment Patterns and Adherence to Bacillus Calmette-Guerin (BCG) in the Context of Guideline Recommendations for Patients with High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC)

ASCO GU 2023: Neoadjuvant Nivolumab + Ipilimumab in Cisplatin-Ineligible Patients with Upper Tract Urothelial Cancer

ASCO GU 2023: A SEER-Medicare Based Quality Score for Patients with Synchronous and Metachronous Metastatic Upper Tract Urothelial Carcinoma and Its Association with Cost of Care and Survival

ASCO GU 2023: Early Outcomes from Lutetium Lu-177 Vipivotide Tetraxetan Treatment in Patients Selected for Therapy with Piflufolastat F-18 PET Imaging

ASCO GU 2023: A Phase II Clinical Study of Intravesical Photo Dynamic Therapy in Patients with BCG-Unresponsive NMIBC (Interim Analysis)

ASCO GU 2023: Chemotherapy, Immunotherapy, or Combination First-Line Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Large Real-World Experience

ASCO GU 2023: SunRISe-4: TAR-200 plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Patients with Muscle-Invasive Bladder Cancer (MIBC) Who Are Ineligible for or Refuse Neoadjuvant Platinum-Based Chemotherapy

ASCO GU 2023: Phase 2 KEYNOTE-057 Cohort C: Pembrolizumab with Vibostolimab or Favezelimab for Patients with High-Risk Bacillus Calmette-Guérin (BCG)-Unresponsive Non–muscle-Invasive Bladder Cancer (NMIBC)

ASCO GU 2023: Phase 3 KEYNOTE-905/EV-303: Perioperative Pembrolizumab (Pembro) or Pembro + Enfortumab Vedotin for Muscle-Invasive Bladder Cancer (MIBC)

ASCO GU 2023: Racial and Geographical Disparities in Pivotal Bladder Cancer Clinical Trials

ASCO GU 2023: A Phase 1, Open-Label Trial to Evaluate Feasibility and Safety of Intramural Injection of Belzupacap Sarotalocan (AU-011) in Non-Muscle–invasive Bladder Cancer (NMIBC)

ASCO GU 2023: Oncologic Outcomes in Patients with Residual Invasive Upper Tract Urothelial Carcinoma Following Neoadjuvant Chemotherapy

ASCO GU 2023: Benefit of Whole-Pelvis Radiation for Patients with Muscle-Invasive Bladder Cancer: An Inverse Probability Treatment-Weighted Analysis

ASCO GU 2023: Use of a Navigable Interface for Integrated Whole Genome and Transcriptome Sequencing as a Platform for Pursuit of Therapeutic Targets in Advanced Prostate Cancers

ASCO GU 2023: The Impact of Genomic Biomarkers on a Validated Clinical Risk Prediction Model for Upgrading/upstaging Among Men with Low-Risk Prostate Cancer

ASCO GU 2023: Phase Ib/II Study of Neoadjuvant Pembrolizumab and Chemotherapy for T2-4aN0M0 Urothelial Cancer (HCRN GU14-188)

ASCO GU 2023: Co-Primary Endpoint Analysis of HCRN GU 16-257: Phase 2 Trial of Gemcitabine, Cisplatin, plus Nivolumab with Selective Bladder Sparing in Patients with Muscle-Invasive Bladder Cancer (MIBC)

ASCO GU 2023: Ability of STAR-CAP Staging System to Prognosticate Risk of Subsequent Therapies After Initial Treatment of M0 Prostate Cancer

1
2
3
4
5
6
7
8
9
10